A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
A phase 2 trial of Alisertib in small-cell lung cancer, run by Puma Biotechnology, Inc., now recruiting.
Overview
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer is a phase 2 interventional study registered as NCT06095505 by Puma Biotechnology, Inc., with 120 participants planned, started 2024-02-08 and due to reach its primary completion in 2027-10-30. Interventions recorded: Alisertib.
Similar pages
not linked directly; found by shared links- TrialA Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Shares Alisertib, Puma Biotechnology and the tag pipeline.
- TrialA Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
Shares Alisertib, Puma Biotechnology, Small-cell lung cancer.
- TrialA Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors
Shares Small-cell lung cancer and the tag pipeline.
- TrialSNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer
Shares Small-cell lung cancer and the tag pipeline.
- TrialAdaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Shares Small-cell lung cancer and the tag pipeline.
- TrialAdaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Shares Small-cell lung cancer and the tag pipeline.
- TrialA Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
Shares Small-cell lung cancer and the tag pipeline.
- TrialPharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms
Shares Small-cell lung cancer and the tag pipeline.